Immatics (IMTX) Receivables (2019 - 2025)
Immatics (IMTX) posted Receivables of $7.1 million for Q4 2025, up 89.84% sequentially from $3.7 million in Q3 2025, and up 13.43% YoY from $6.3 million in Q4 2024.
Immatics (IMTX) Receivables (2019 - 2025) Analysis & Trends
Immatics has reported Receivables for 7 years, with the latest figure at $7.1 million in Q4 2025.
- Quarterly Receivables rose 13.43% year-over-year to $7.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.1 million (up 13.43% YoY) and the FY2025 annual result came in at $6.9 million, up 8.7% from the prior year.
- Receivables climbed to $7.1 million in Q4 2025 per IMTX's latest filing, from $3.7 million in the prior quarter.
- Over five years, Receivables peaked at $7.1 million in Q4 2025 and troughed at $247942.0 in Q1 2023.
- A 5-year average of $2.3 million and a median of $1.1 million in 2022 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2024: Receivables tumbled 70.23% in 2023, then surged 742.4% in 2024.
- Over 5 years, Receivables stood at $780188.2 in 2021, then jumped by 45.28% to $1.1 million in 2022, then jumped by 288.52% to $4.4 million in 2023, then surged by 42.12% to $6.3 million in 2024, then climbed by 13.43% to $7.1 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $7.1 million, $3.7 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 7.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.10 Mn |
| Sep 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | 2.22 Mn |
| Mar 31, 2025 | 5.89 Mn |
| Dec 31, 2024 | 6.26 Mn |
| Sep 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Mar 31, 2024 | 1.93 Mn |
| Dec 31, 2023 | 4.40 Mn |
| Sep 30, 2023 | 559,535.51 |
| Jun 30, 2023 | 359,345.05 |
| Mar 31, 2023 | 247,941.96 |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | 1.15 Mn |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 832,774.59 |
| Dec 31, 2021 | 780,188.19 |
| Sep 30, 2021 | 854,983.31 |
| Jun 30, 2021 | 864,666.89 |
| Mar 31, 2021 | 693,585.76 |